Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHongjia ZhuHGHongfei GuImmunité et CancerXLXiangping Li

Discussion

Loading...

Member takes

Implication

Observational analysis shows significant reductions in overall response rate in R/R DLBCL patients receiving glofitamab before leukapheresis, indicating implications for T-cell activation.

Key Points

  • Glofitamab exposure significantly reduced overall response rate to CAR-T therapy in patients with R/R DLBCL.
  • In the exposed group, 33% achieved overall response compared to 80% in the unexposed group, revealing a stark difference.
  • T-cell activation was further analyzed through logistic regression, indicating exposure as an independent risk factor.
  • Results suggest a need for a longer glofitamab washout period and multicenter clinical studies to confirm findings.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddbdhttps://doi.org/10.1182/blood-2025-2382
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025 · 1 citations
  2. 2Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025
  3. 3Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  4. 4A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL)2025
  5. 5Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025